Resistance_NN to_TO Macrolides_NP and_CC Related_JJ Antibiotics_NNS in_IN Streptococcus_NP pneumoniae_NNS null_JJ Macrolides_NP have_VBP a_DT common_JJ structure_NN formed_VBN by_IN a_DT large_JJ lactone_NN ring_NN ._SENT Erythromycin_NN is_VBZ a_DT mixture_NN of_IN antibiotics_NNS that_WDT includes_VBZ erythromycin_NN A_NP ,_, which_WDT is_VBZ the_DT active_JJ compound_NN and_CC which_WDT has_VBZ a_DT 14-membered_JJ lactone_NN ring_NN with_IN two_CD sugars_NNS ,_, l-cladinose_NN and_CC an_DT amino_NN sugar_NN ._SENT Other_JJ commercially_RB available_JJ macrolides_NNS derived_VBN from_IN erythromycin_NN A_DT include_VBP clarithromycin_NN ,_, dirithromycin_NP ,_, roxithromycin_NN ,_, and_CC azithromycin_NN ,_, which_WDT has_VBZ an_DT enlarged_JJ ,_, 15-membered_JJ ring_NN resulting_VBG from_IN a_DT nitrogen_NN insertion_NN ._SENT The_DT structural_JJ modifications_NNS of_IN erythromycin_NN A_DT resulted_VBN in_IN improved_VBN pharmacokinetic_JJ profiles_NNS and_CC better_JJR tolerance_NN ,_, but_CC cross-resistance_NN between_IN members_NNS of_IN this_DT class_NN of_IN antimicrobial_JJ agents_NNS was_VBD still_RB observed_VBN ._SENT Certain_JJ 16-membered_JJ macrolides_NNS are_VBP also_RB available_JJ in_IN a_DT few_JJ countries_NNS (_( spiramycin_NP ,_, josamycin_NP ,_, midecamycin_NN ,_, and_CC miocamycin_NN )_) or_CC for_IN veterinary_JJ use_NN (_( tylosin_NN )_) ._SENT The_DT recently_RB developed_VBN ketolides_NNS telithromycin_NN and_CC ABT773_NP are_VBP derived_VBN from_IN clarithromycin_NN and_CC have_VBP two_CD major_JJ modifications_NNS ,_, replacement_NN of_IN l-cladinose_NN by_IN a_DT keto_NN function_NN and_CC an_DT 11-_CD to_TO 12-carbamate_JJ extension_NN with_IN an_DT arylalkyl_NN modification_NN in_IN telithromycin_NN ,_, the_DT latter_NN of_IN which_WDT may_MD partially_RB explain_VB its_PP$ increased_VBN intrinsic_JJ activity_NN and_CC activity_NN against_IN erythromycin-resistant_JJ strains_NNS ,_, as_RB discussed_VBN below_RB ._SENT In_IN telithromycin_NP and_CC ABT773_NP ,_, modification_NN at_IN the_DT C-6_NP position_NN prevents_VBZ inactivation_NN of_IN the_DT molecule_NN in_IN acid_JJ medium_NN ._SENT The_DT ribosome_NN structure_NN and_CC contact_NN points_NNS between_IN the_DT ribosome_NN and_CC erythromycin_NN A_DT were_VBD recently_RB identified_VBN by_IN crystallography_NN studies_NNS ._SENT The_DT bacterial_JJ ribosome_NN is_VBZ formed_VBN by_IN a_DT small_JJ ,_, 30S_JJ subunit_NN and_CC a_DT large_JJ ,_, 50S_JJ subunit_NN ._SENT The_DT latter_NN is_VBZ composed_VBN of_IN 23S_JJ rRNA_NN and_CC of_IN a_DT minimum_NN of_IN 30_CD proteins_NNS ._SENT The_DT secondary_JJ structure_NN of_IN 23S_JJ rRNA_NN is_VBZ folded_VBN due_RB to_TO base_VB pairing_VBG and_CC forms_VBZ six_CD domains_NNS numbered_VBD I_PP to_TO VI_NP ,_, while_IN the_DT tertiary_JJ structure_NN of_IN the_DT molecule_NN is_VBZ maintained_VBN by_IN its_PP$ interactions_NNS with_IN proteins_NNS ._SENT Stoichiometric_JJ binding_NN of_IN erythromycin_NN A_DT to_TO the_DT 50S_JJ subunit_NN causes_VBZ inhibition_NN of_IN protein_NN synthesis_NN ._SENT The_DT binding_JJ site_NN of_IN erythromycin_NN is_VBZ composed_VBN of_IN domain_NN V_CD sequences_NNS near_IN the_DT peptidyltransferase_NN center_NN ,_, where_WRB the_DT polypeptide_NN chain_NN is_VBZ synthesized_VBN ._SENT Hairpin_NN 35_CD in_IN domain_NN II_NP is_VBZ in_IN the_DT vicinity_NN of_IN this_DT binding_JJ site_NN ._SENT High-resolution_NN X-ray_NN structures_NNS of_IN the_DT 50S_JJ ribosomal_JJ subunit_NN of_IN Deinococcusradiodurans_NP complexed_VBD with_IN erythromycin_NN A_NP showed_VBD that_IN the_DT 2'-OH_JJ group_NN of_IN the_DT desosamine_JJ sugar_NN of_IN the_DT antibiotic_NN appears_VBZ to_TO form_VB three_CD hydrogen_NN bonds_NNS with_IN adenines_NNS at_IN positions_NNS 2058_CD and_CC 2059_CD (_( Escherichiacoli_NP numbering_VBG )_) ._SENT The_DT dimethylamino_NN group_NN of_IN the_DT desosamine_NN sugar_NN also_RB appears_VBZ to_TO interact_VB with_IN A2505_NP ._SENT The_DT 6-OH_NN of_IN the_DT lactone_NN ring_NN may_MD form_VB a_DT hydrogen_NN bond_NN with_IN A2062_NP ,_, the_DT 11-OH_NP and_CC 12-OH_NP may_MD form_VB one_CD hydrogen_NN bond_NN with_IN U2609_NP ,_, but_CC the_DT cladinose_JJ sugar_NN does_VBZ not_RB seem_VB to_TO be_VB involved_VBN in_IN interactions_NNS with_IN 23S_JJ rRNA_NN ._SENT Although_IN footprinting_NN experiments_NNS have_VBP implicated_VBN adenine_NN at_IN position_NN 752_CD (_( domain_NN II_CD )_) in_IN the_DT binding_NN of_IN erythromycin_NN ,_, no_DT direct_JJ interaction_NN has_VBZ been_VBN shown_VBN between_IN the_DT two_CD structures_NNS ,_, at_IN least_JJS in_IN the_DT ribosome_NN of_IN D._NP radiodurans_NNS ._SENT The_DT binding_JJ site_NN of_IN erythromycin_NN A_DT is_VBZ located_VBN within_IN the_DT tunnel_NN that_WDT serves_VBZ as_IN a_DT channel_NN for_IN the_DT growing_VBG peptide_NN ._SENT The_DT surface_NN of_IN this_DT tunnel_NN is_VBZ formed_VBN by_IN domains_NNS I_PP to_TO V_CD of_IN 23S_JJ rRNA_NN ,_, by_IN several_JJ ribosomal_JJ proteins_NNS including_VBG the_DT globular_JJ structures_NNS of_IN ribosomal_JJ proteins_NNS L22_NP and_CC L4_NP ,_, and_CC by_IN a_DT beta_JJ hairpin_NN of_IN L22_NP ._SENT Erythromycin_NN does_VBZ not_RB inhibit_VB the_DT peptidyltransferase_NN activity_NN but_CC prevents_VBZ the_DT extension_NN of_IN the_DT peptide_NN chain_NN by_IN blocking_VBG the_DT polypeptide_NN exit_NN tunnel_NN and_CC provokes_VBZ the_DT premature_JJ release_NN of_IN peptidyl-tRNA_NN ._SENT Moreover_RB ,_, erythromycin_NN also_RB prevents_VBZ ribosomal_JJ assembly_NN at_IN an_DT early_JJ stage_NN of_IN protein_NN synthesis_NN ._SENT A_DT common_JJ mechanism_NN shared_VBN by_IN bacteria_NNS for_IN becoming_VBG resistant_JJ to_TO antimicrobial_JJ agents_NNS is_VBZ the_DT diminution_NN of_IN the_DT affinity_NN of_IN the_DT antibiotic_NN for_IN its_PP$ target_NN ._SENT This_DT effect_NN may_MD result_VB from_IN enzymatic_JJ detoxification_NN of_IN the_DT drug_NN or_CC ,_, conversely_RB ,_, from_IN target_NN modification_NN ._SENT A_DT third_JJ possibility_NN is_VBZ diminished_VBN access_NN to_TO the_DT target_NN secondary_JJ to_TO active_JJ efflux_NN or_CC decreased_VBD uptake_NN of_IN the_DT molecules_NNS ._SENT The_DT resistance_NN of_IN Streptococcuspneumoniae_NP to_TO erythromycin_NN is_VBZ due_JJ to_TO modification_NN of_IN the_DT ribosomal_JJ target_NN by_IN methylation_NN or_CC mutation_NN and_CC active_JJ efflux_NN of_IN the_DT drug_NN ;_: drug_NN modification_NN has_VBZ not_RB been_VBN reported_VBN in_IN this_DT species_NN ._SENT THE_DT MLSB_NP RESISTANCE_NP PHENOTYPE_NP :_: As_RB already_RB mentioned_VBN ,_, ribosomal_JJ modification_NN by_IN methylation_NN was_VBD the_DT first_JJ mechanism_NN of_IN resistance_NN to_TO erythromycin_NN elucidated_VBD and_CC remained_VBD unique_JJ for_IN decades_NNS ._SENT It_PP is_VBZ secondary_JJ to_TO the_DT acquisition_NN of_IN an_DT erm_NN gene_NN (_( erythromycin_NN ribosome_NN methylase_NN )_) usually_RB carried_VBD by_IN transposable_JJ elements_NNS in_IN pneumococci_NNS ._SENT This_DT gene_NN encodes_VBZ a_DT ribosomal_JJ methylase_NN which_WDT dimethylates_VBZ pneumococcal_JJ 23S_JJ rRNA_NN at_IN a_DT single_JJ site_NN ,_, adenine_NN at_IN position_NN 2058_CD ._SENT As_IN previously_RB alluded_VBN to_TO ,_, the_DT A2058_NP nucleotide_NN is_VBZ a_DT key_JJ nucleotide_NN for_IN the_DT binding_NN of_IN erythromycin_NN ._SENT The_DT modification_NN markedly_RB reduces_VBZ the_DT affinity_NN of_IN erythromycin_NN for_IN its_PP$ target_NN ,_, probably_RB by_IN preventing_VBG direct_JJ access_NN to_TO the_DT target_NN or_CC by_IN modifying_VBG the_DT conformation_NN of_IN the_DT binding_JJ site_NN ._SENT Cross-resistance_NN to_TO macrolides_NNS ,_, lincosamides_NNS ,_, and_CC streptogramin_NP B_NP antibiotics_NNS ,_, which_WDT gave_VBD its_PP$ name_NN to_TO the_DT MLSB_NP resistance_NN phenotype_NN ,_, is_VBZ due_JJ to_TO the_DT overlapping_JJ binding_JJ sites_NNS of_IN the_DT drugs_NNS ._SENT TABLE_NN 1_CD |_SYM Macrolide-lincosamide-streptogramin_NP B_NP resistance_NN in_IN S._NP pneumoniae_NNS due_JJ to_TO gene_NN acquisition_NN The_DT erm(B)_JJ determinant_NN ,_, initially_RB called_VBN erm(AM)_NN ,_, was_VBD first_RB characterized_VBN on_IN plasmid_NN pAM77_JJ in_IN Streptococcussanguis_NP A1_JJ isolated_VBN from_IN dental_JJ plaque_NN in_IN 1978_CD ._SENT The_DT gene_NN is_VBZ widely_RB distributed_VBN ,_, not_RB only_RB in_IN S._NP pneumoniae_NNS but_CC also_RB in_IN a_DT variety_NN of_IN other_JJ streptococcal_JJ and_CC enterococcal_JJ species_NNS ,_, in_IN enterobacteria_NN ,_, and_CC in_IN staphylococci_NNS ,_, indicating_VBG easy_JJ exchange_NN of_IN genetic_JJ information_NN even_RB between_IN phylogenetically_RB remote_JJ species_NNS ._SENT In_IN pneumococci_NNS ,_, the_DT gene_NN is_VBZ borne_VBN by_IN conjugative_JJ transposons_NNS related_VBN to_TO Tn1545_NP ,_, Tn1545-like_JJ elements_NNS ,_, or_CC a_DT Tn917-like_JJ element_NN that_WDT is_VBZ part_NN of_IN a_DT larger_JJR composite_JJ transposon_NN ,_, Tn3872_NP ._SENT Transposition_NN occurs_VBZ from_IN chromosome_NN to_TO chromosome_NN of_IN strains_NNS of_IN S._NP pneumoniae_NNS ._SENT Both_DT clonal_JJ spread_NN of_IN resistant_JJ strains_NNS and_CC horizontal_JJ transfer_NN of_IN the_DT element_NN account_NN for_IN the_DT high_JJ prevalence_NN of_IN the_DT erm(B)_JJ gene_NN in_IN erythromycin-resistant_JJ pneumococci_NNS in_IN certain_JJ countries_NNS ._SENT In_IN one_CD study_NN ,_, sequences_NNS homologous_JJ to_TO the_DT structural_JJ gene_NN for_IN the_DT integrase_NN of_IN Tn1545_NP ,_, an_DT enzyme_NN required_VBN for_IN the_DT movements_NNS of_IN the_DT element_NN ,_, were_VBD found_VBN in_IN all_DT 36_CD S._NP pneumoniae_NNS strains_NNS resistant_JJ to_TO erythromycin_NN studied_VBD ._SENT Strains_NNS belonging_VBG to_TO the_DT 23F_JJ or_CC 6B_JJ lineage_NN appear_VBP to_TO have_VB erm(B)_NN as_IN part_NN of_IN Tn3872_NP or_CC a_DT modified_JJ form_NN of_IN Tn916_NP and_CC Tn1545_NP ._SENT Tn1545-like_JJ elements_NNS may_MD also_RB be_VB exchanged_VBN between_IN pneumococci_NNS by_IN transformation_NN ._SENT However_RB ,_, this_DT mode_NN of_IN transfer_NN ,_, which_WDT is_VBZ considered_VBN essential_JJ for_IN the_DT spread_NN of_IN beta-lactam_NN resistance_NN by_IN alteration_NN of_IN genes_NNS for_IN penicillin_NN binding_VBG proteins_NNS in_IN pneumococci_NNS ,_, has_VBZ not_RB been_VBN shown_VBN for_IN erythromycin_NN resistance_NN ._SENT Although_IN widely_RB predominant_JJ ,_, erm(B)_NN is_VBZ not_RB the_DT only_JJ representative_NN of_IN the_DT erm_JJ gene_NN class_NN in_IN pneumococci_NNS ._SENT The_DT presence_NN of_IN an_DT erm(A)_JJ gene_NN has_VBZ been_VBN reported_VBN for_IN a_DT single_JJ strain_NN ,_, isolated_VBN in_IN Greece_NP ,_, to_TO which_WDT it_PP conferred_VBD cross-resistance_NN to_TO erythromycin_NN and_CC clindamycin_NN and_CC for_IN one_CD strain_NN with_IN a_DT resident_JJ erm(B)_NN gene_NN ._SENT This_DT determinant_NN ,_, first_RB detected_VBN in_IN Streptococcuspyogenes_NP ,_, was_VBD initially_RB designated_VBN ermTR_NN and_CC was_VBD subsequently_RB included_VBN in_IN the_DT erm(A)_JJ gene_NN class_NN because_IN of_IN its_PP$ close_JJ relatedness_NN to_TO erm(A)_NN in_IN Staphylococcusaureus_NP ._SENT The_DT methylase_NN encoded_VBN by_IN erm(B)_NN may_MD be_VB constitutively_RB or_CC inducibly_RB synthesized_VBN ._SENT When_WRB expression_NN is_VBZ constitutive_JJ ,_, the_DT erm(B)_JJ mRNA_NN is_VBZ active_JJ ,_, and_CC its_PP$ translation_NN by_IN the_DT ribosomes_NNS allows_VBZ constitutive_JJ methylation_NN of_IN the_DT ribosomes_NNS ,_, probably_RB while_IN they_PP are_VBP synthesized_VBN ._SENT When_WRB resistance_NN is_VBZ inducible_JJ ,_, erm(B)_JJ mRNA_NN is_VBZ synthesized_VBN ,_, but_CC in_IN an_DT inactive_JJ conformation_NN ,_, and_CC becomes_VBZ active_JJ only_RB in_IN the_DT presence_NN of_IN inducing_VBG macrolides_NNS ._SENT Although_IN for_IN erm(B)_NN the_DT mechanism_NN of_IN induction_NN has_VBZ not_RB been_VBN thoroughly_RB studied_VBN ,_, a_DT model_NN which_WDT can_MD be_VB inferred_VBN from_IN the_DT translational_JJ regulation_NN model_NN of_IN erm(C)_NN in_IN S._NP aureus_NN has_VBZ been_VBN proposed_VBN and_CC can_MD be_VB summarized_VBN as_RB follows_VBZ ._SENT The_DT 5_CD '_POS end_NN of_IN erm(B)_NN presents_VBZ a_DT series_NN of_IN inverted_JJ repeats_NNS which_WDT are_VBP responsible_JJ for_IN the_DT lack_NN of_IN methylase_NN synthesis_NN in_IN the_DT absence_NN of_IN erythromycin_NN ._SENT Fourteen_NN pairs_NNS of_IN repeats_NNS have_VBP been_VBN identified_VBN which_WDT could_MD form_VB alternative_JJ stem-loop_NN structures_NNS by_IN base_NN pairing_VBG ._SENT As_IN shown_VBN in_IN Fig._NN ,_, one_CD of_IN these_DT stem-loops_NN sequesters_VBZ the_DT ribosome_NN binding_VBG site_NN and_CC initiation_NN codon_NN for_IN the_DT methylase_NN ._SENT Thus_RB ,_, the_DT methylase_NN cannot_MD be_VB produced_VBN ,_, since_IN the_DT initiation_NN motifs_NNS for_IN translation_NN of_IN the_DT enzyme_NN are_VBP not_RB accessible_JJ to_TO the_DT ribosomes_NNS ._SENT Induction_NN is_VBZ related_VBN to_TO the_DT presence_NN of_IN sequences_NNS coding_VBG for_IN a_DT small_JJ leader_NN peptide_NN of_IN 36_CD amino_NN acids_NNS upstream_RB from_IN the_DT methylase_NN gene_NN ._SENT In_IN the_DT presence_NN of_IN low_JJ concentrations_NNS of_IN erythromycin_NN ,_, binding_VBG of_IN the_DT antibiotic_NN to_TO a_DT ribosome_NN translating_VBG the_DT leader_NN peptide_NN causes_VBZ the_DT ribosome_NN to_TO stall_VB ,_, in_IN turn_NN destabilizing_VBG the_DT pairing_VBG of_IN the_DT inverted_JJ repeats_NNS and_CC inducing_VBG conformational_JJ rearrangements_NNS in_IN the_DT mRNA_NN ._SENT In_IN particular_JJ ,_, displacement_NN of_IN the_DT stem-loop_NN shown_VBN in_IN Fig._NN unmasks_VBZ the_DT initiation_NN sequences_NNS for_IN the_DT methylase_NN ,_, allowing_VBG synthesis_NN to_TO proceed_VB by_IN the_DT ribosomes_NNS that_WDT are_VBP not_RB complexed_VBN with_IN erythromycin_NN or_CC by_IN those_DT that_WDT are_VBP methylated_VBN ._SENT Methylation_NN of_IN some_DT ribosomes_NNS might_MD occur_VB through_IN transient_JJ rearrangements_NNS of_IN the_DT stem-loop_NN structures_NNS ,_, which_WDT would_MD lead_VB to_TO the_DT synthesis_NN of_IN a_DT basal_JJ level_NN of_IN the_DT methylase_NN ._SENT For_IN a_DT given_VBN erm_NN gene_NN ,_, the_DT inducing_VBG capacity_NN of_IN the_DT macrolides_NN depends_VBZ on_IN the_DT antibiotic_JJ structure_NN ._SENT The_DT global_JJ structure_NN of_IN the_DT drug_NN ,_, rather_RB than_IN the_DT number_NN of_IN atoms_NNS in_IN the_DT lactone_NN ring_NN ,_, determines_VBZ the_DT inducing_VBG capacity_NN of_IN a_DT macrolide_NN ._SENT As_IN an_DT example_NN ,_, erythromycin_NN is_VBZ an_DT inducer_NN for_IN the_DT production_NN of_IN most_JJS Erm_UH methylases_NNS ,_, whereas_IN ketolides_NNS ,_, which_WDT have_VBP a_DT similar_JJ lactone_NN ring_NN ,_, are_VBP not_RB ._SENT A_DT lack_NN of_IN inducing_VBG ability_NN of_IN ketolides_NNS has_VBZ been_VBN related_VBN to_TO the_DT replacement_NN of_IN one_CD of_IN the_DT erythromycin_NN sugars_NNS ,_, l-cladinose_NN ,_, by_IN a_DT keto_NN function_NN ._SENT It_PP is_VBZ likely_JJ that_IN the_DT intimate_JJ mode_NN of_IN action_NN of_IN a_DT macrolide_NN determines_VBZ its_PP$ capacity_NN to_TO act_VB as_IN an_DT inducer_NN ,_, since_IN proper_JJ ribosome_NN stalling_VBG is_VBZ required_VBN for_IN the_DT induction_NN of_IN methylase_NN production_NN ._SENT For_IN erm(B)_NN ,_, the_DT commercially_RB available_JJ macrolides_NNS (_( including_VBG the_DT 14-_CD ,_, 15-_CD ,_, and_CC 16-membered_JJ macrolides_NNS )_) ,_, lincosamides_NNS ,_, and_CC streptogramin_NP B_NP antibiotics_NNS are_VBP inducers_NNS of_IN methylase_NN synthesis_NN to_TO various_JJ degrees_NNS ,_, leading_VBG to_TO cross-resistance_NN to_TO these_DT antimicrobial_JJ agents_NNS ._SENT It_PP has_VBZ been_VBN shown_VBN for_IN erm(A)_NN and_CC erm(C)_NN ,_, both_CC in_IN laboratory_NN mutants_NNS and_CC in_IN clinical_JJ isolates_NNS ,_, that_DT constitutive_JJ expression_NN is_VBZ due_JJ to_TO deletions_NNS ,_, duplications_NNS ,_, or_CC point_NN mutations_NNS in_IN the_DT attenuator_NN sequence_NN leading_VBG to_TO derepressed_JJ production_NN of_IN the_DT methylase_NN ._SENT In_IN pneumococci_NNS ,_, the_DT constitutive_JJ expression_NN of_IN MLSB_NP resistance_NN is_VBZ infrequently_RB found_VBN ._SENT However_RB ,_, despite_IN the_DT fact_NN that_IN the_DT vast_JJ majority_NN of_IN pneumococci_NNS express_VBP erythromycin_NN resistance_NN inducibly_RB ,_, it_PP has_VBZ been_VBN shown_VBN by_IN primer_JJR extension_NN analysis_NN of_IN five_CD strains_NNS that_IN various_JJ proportions_NNS of_IN ribosomes_NNS are_VBP methylated_VBN even_RB in_IN the_DT absence_NN of_IN erythromycin_NN ._SENT This_DT paradox_NN has_VBZ been_VBN explained_VBN for_IN certain_JJ strains_NNS by_IN the_DT presence_NN of_IN mutations_NNS in_IN the_DT stem-loop_NN structure_NN that_WDT sequester_VBP the_DT initiation_NN sequences_NNS for_IN the_DT methylase_NN ._SENT Fusion_NN of_IN the_DT mutated_VBN erm(B)_NN attenuator_NN with_IN a_DT lacZ_NP reporter_NN gene_NN has_VBZ confirmed_VBN that_IN the_DT expression_NN of_IN the_DT methylase_NN can_MD be_VB partly_RB derepressed_VBN in_IN certain_JJ strains_NNS ._SENT Other_JJ additional_JJ features_NNS ,_, such_JJ as_IN differences_NNS in_IN the_DT promoter_NN strength_NN or_CC in_IN the_DT copy_NN number_NN of_IN the_DT erm(B)_JJ gene_NN ,_, may_MD also_RB account_VB for_IN the_DT various_JJ levels_NNS of_IN ribosomal_JJ methylation_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Schematic_NP representation_NN of_IN the_DT structure_NN of_IN the_DT mRNA_NN from_IN the_DT inducible_JJ erm(B)_NN gene_NN from_IN pAM77_JJ ._SENT Schematic_JJ representation_NN of_IN the_DT structure_NN of_IN the_DT mRNA_NN from_IN the_DT inducible_JJ erm(B)_NN gene_NN from_IN pAM77_JJ ._SENT The_DT sequences_NNS of_IN the_DT control_NN peptide_NN (_( hatched_VBN box_NN )_) and_CC of_IN the_DT methylase_NN [_SYM (_( erm(B)_NN ]_SYM are_VBP shown_VBN ._SENT Numbers_NNS 1_CD to_TO 14_CD indicate_VBP inverted_JJ repeats_NNS with_IN their_PP$ symmetry_NN axes_NNS (_( solid_JJ ovals_NNS flanked_VBN by_IN broken_VBN lines_NNS )_) ._SENT The_DT secondary_JJ structure_NN which_WDT is_VBZ putatively_RB formed_VBN by_IN inverted_JJ repeat_NN 14_CD and_CC which_WDT would_MD sequester_VB the_DT initiation_NN sequence_NN for_IN the_DT methylase_NN in_IN the_DT absence_NN of_IN erythromycin_NN is_VBZ shown_VBN at_IN the_DT right_NN ._SENT RBS_NP ,_, ribosome_NN binding_JJ site_NN ._SENT Physiological_JJ pumps_NNS conferring_VBG erythromycin_NN resistance_NN by_IN efflux_NN have_VBP been_VBN described_VBN for_IN several_JJ gram-positive_JJ organisms_NNS ,_, such_JJ as_IN Cmr_NP from_IN Corynebacteriumglutamicum_NP ,_, which_WDT belongs_VBZ to_TO the_DT major_JJ facilitator_NN superfamily_NN class_NN of_IN pumps_NNS ,_, but_CC not_RB for_IN S._NP pneumoniae_NNS ._SENT However_RB ,_, acquired_VBD resistance_NN to_TO macrolides_NNS conferred_VBN by_IN active_JJ efflux_NN has_VBZ been_VBN detected_VBN recently_RB in_IN this_DT species_NN ._SENT The_DT gene_NN responsible_JJ for_IN efflux_NN was_VBD initially_RB called_VBN mefE_NP and_CC was_VBD subsequently_RB assigned_VBN to_TO the_DT mef(A)_JJ gene_NN class_NN because_IN of_IN its_PP$ close_JJ relatedness_NN to_TO the_DT mefA_NN gene_NN in_IN S._NP pyogenes_NNS ._SENT The_DT Mef(A)_NP pump_NN belongs_VBZ to_TO the_DT major_JJ facilitator_NN superfamily_NN class_NN ._SENT It_PP contains_VBZ 12_CD transmembrane_NN domains_NNS spanning_VBG the_DT cytoplasmic_JJ membrane_NN ,_, and_CC efflux_NN is_VBZ driven_VBN by_IN the_DT proton_NN motive_NN force_NN ._SENT Few_JJ substrates_NNS have_VBP been_VBN identified_VBN ,_, and_CC the_DT pump_NN seems_VBZ to_TO be_VB specific_JJ to_TO erythromycin_NN and_CC its_PP$ derivatives_NNS ,_, including_VBG azithromycin_NN ._SENT Resistance_NN appears_VBZ to_TO be_VB induced_VBN with_IN erythromycin_NN and_CC is_VBZ expressed_VBN at_IN moderate_JJ levels_NNS ,_, with_IN erythromycin_NN MICs_NNS of_IN between_IN 1_CD and_CC 64_CD mug/ml_NN (_( generally_RB between_IN 8_CD and_CC 32_CD mug/ml_NN )_) ._SENT Because_IN the_DT 16-membered_JJ macrolides_NNS ,_, the_DT lincosamides_NNS ,_, and_CC the_DT streptogramin_NN B_NN antibiotics_NNS are_VBP not_RB substrates_NNS of_IN the_DT pump_NN ,_, these_DT antimicrobial_JJ agents_NNS remain_VBP active_JJ ,_, even_RB after_IN induction_NN with_IN erythromycin_NN ._SENT Resistance_NN to_TO erythromycin_NN combined_VBN with_IN susceptibility_NN to_TO clindamycin_NN ,_, whether_IN the_DT cells_NNS are_VBP induced_VBN or_CC not_RB induced_VBN with_IN erythromycin_NN ,_, defines_VBZ the_DT M_NP resistance_NN phenotype_NN ._SENT The_DT mef(A)_JJ gene_NN is_VBZ transferable_JJ among_IN pneumococci_NNS and_CC is_VBZ a_DT member_NN of_IN a_DT group_NN of_IN closely_RB related_JJ ,_, large_JJ transposable_JJ elements_NNS ._SENT Although_IN the_DT 7,244-bp_NP transposon_NP Tn1207.1_NP is_VBZ apparently_RB intact_JJ ,_, it_PP is_VBZ defective_JJ for_IN transfer_NN ,_, as_IN is_VBZ the_DT 5.4-_CD to_TO 5.5-kb_NP MEGA_NP element_NN ,_, which_WDT is_VBZ devoid_JJ of_IN the_DT transposase_NN gene_NN ._SENT Downstream_RB from_IN mef(A)_NN lies_VBZ a_DT gene_NN that_WDT putatively_RB encodes_VBZ an_DT ATP_NP binding_JJ cassette_NN transporter_NN and_CC whose_WP$ role_NN in_IN the_DT expression_NN of_IN resistance_NN remains_VBZ questionable_JJ ._SENT The_DT cloned_VBN mef(A)_NN gene_NN alone_RB is_VBZ sufficient_JJ to_TO confer_VB resistance_NN ,_, although_IN it_PP is_VBZ not_RB possible_JJ to_TO exclude_VB the_DT possibility_NN that_IN the_DT pump_NN interacts_VBZ with_IN other_JJ proteins_NNS ._SENT Both_DT ribosomal_JJ methylation_NN and_CC drug_NN efflux_NN alter_VB the_DT activities_NNS of_IN erythromycin_NN A_NP and_CC its_PP$ derivatives_NNS ._SENT Several_JJ strategies_NNS should_MD allow_VB MLSB_NP resistance_NN in_IN pneumococci_NNS to_TO be_VB overcome_VBN :_: the_DT use_NN of_IN methylase_NN or_CC efflux_NN inhibitors_NNS ,_, synergistic_JJ combinations_NNS with_IN another_DT antimicrobial_JJ agents_NNS ,_, and_CC the_DT development_NN of_IN noninducing_NN macrolides_NNS or_CC of_IN macrolides_NNS that_WDT have_VBP alternative_JJ ribosome_NN binding_VBG sites_NNS or_CC that_WDT are_VBP not_RB substrates_NNS for_IN the_DT efflux_NN pump_NN ._SENT Two_CD types_NNS of_IN drugs_NNS have_VBP been_VBN developed_VBN with_IN activities_NNS against_IN MLSB-resistant_JJ pneumococci_NNS ,_, the_DT streptogramins_NNS and_CC the_DT ketolides_NNS ._SENT The_DT streptogramins_NNS (_( pristinamycin_NN and_CC quinupristin-dalfopristin_NN )_) are_VBP composed_VBN of_IN two_CD streptogramin_NN factors_NNS ,_, A_NP and_CC B_NP ,_, with_IN synergistic_JJ activity_NN resulting_VBG from_IN a_DT dual_JJ interaction_NN with_IN the_DT ribosome_NN ._SENT As_IN mentioned_VBN above_IN ,_, Erm_UH methylation_NN of_IN the_DT ribosome_NN affects_VBZ the_DT activity_NN of_IN the_DT B_NP component_NN ._SENT However_RB ,_, synergy_NN is_VBZ maintained_VBN ,_, most_RBS probably_RB because_IN of_IN the_DT mode_NN of_IN action_NN of_IN the_DT streptogramins_NNS ._SENT Although_IN the_DT mechanism_NN for_IN synergy_NN is_VBZ not_RB fully_RB understood_VBN ,_, the_DT binding_NN of_IN factor_NN A_DT to_TO its_PP$ target_NN may_MD induce_VB a_DT conformational_JJ change_NN in_IN the_DT ribosome_NN leading_VBG to_TO an_DT increase_NN in_IN its_PP$ affinity_NN for_IN factor_NN B_NN ._SENT The_DT ribosomal_JJ alteration_NN must_MD be_VB sufficiently_RB marked_VBN to_TO overcome_VB the_DT loss_NN of_IN affinity_NN for_IN the_DT B_NP molecule_NN that_IN results_NNS from_IN rRNA_NN methylation_NN ._SENT The_DT bactericidal_JJ activity_NN of_IN the_DT streptogramin_NN combination_NN against_IN pneumococci_NNS is_VBZ also_RB generally_RB conserved_VBN in_IN vitro_NN ._SENT The_DT ketolides_NNS ,_, like_IN the_DT macrolides_NNS ,_, bind_NN to_TO the_DT bacterial_JJ ribosome_NN and_CC exert_VB their_PP$ antibacterial_NN effect_NN by_IN inhibition_NN of_IN protein_NN synthesis_NN ._SENT Despite_IN the_DT similarity_NN between_IN the_DT macrolides_NNS and_CC the_DT ketolides_NNS ,_, in_IN terms_NNS of_IN mechanism_NN of_IN action_NN and_CC therefore_RB cross-resistance_NN ,_, recent_JJ data_NNS indicated_VBD that_IN the_DT ketolides_NNS have_VBP activity_NN against_IN MLSB-resistant_JJ pneumococci_NNS ._SENT This_DT finding_NN appears_VBZ to_TO be_VB due_JJ to_TO two_CD differences_NNS from_IN the_DT macrolides_NNS :_: the_DT strength_NN and_CC nature_NN of_IN ribosome_NN binding_NN and_CC the_DT weak_JJ ability_NN of_IN the_DT ketolides_NNS to_TO act_VB as_IN inducers_NNS of_IN macrolide_NN resistance_NN ._SENT It_PP has_VBZ been_VBN shown_VBN that_IN macrolides_NNS interact_VBP with_IN two_CD sites_NNS within_IN the_DT bacterial_JJ ribosome_NN ,_, domains_NNS II_NP and_CC V_CD of_IN 23S_JJ rRNA_NN ,_, with_IN the_DT interaction_NN at_IN domain_NN II_NP being_VBG relatively_RB weak_JJ ._SENT The_DT ketolides_NNS also_RB interact_VBP with_IN domains_NNS II_NP and_CC V_CD but_CC appear_VBP to_TO have_VB a_DT 10-fold_NN higher_RBR binding_JJ affinity_NN ._SENT As_RB discussed_VBN previously_RB ,_, MLSB_NP resistance_NN arises_VBZ when_WRB the_DT binding_NN of_IN the_DT macrolides_NNS within_IN domain_NN V_NN is_VBZ compromised_VBN ,_, principally_RB through_IN methylation_NN ._SENT In_IN contrast_NN ,_, the_DT ketolides_NNS retain_VBP in_IN part_NN their_PP$ ability_NN to_TO bind_VB to_TO MLSB-resistant_JJ ribosomes_NNS probably_RB because_IN of_IN their_PP$ stronger_JJR interaction_NN with_IN domain_NN II_NP ._SENT However_RB ,_, as_IN previously_RB mentioned_VBN ,_, crystal_NN studies_NNS with_IN D._NP radiodurans_NP 50S_NP ribosomal_JJ subunits_NN do_VBP not_RB support_VB the_DT notion_NN of_IN direct_JJ contacts_NNS between_IN the_DT 14-membered_JJ macrolides_NNS and_CC A752_NP or_CC any_DT other_JJ domain_NN II_NP residue_NN ._SENT Alone_RB ,_, the_DT increased_VBN ribosome_NN binding_VBG property_NN probably_RB does_VBZ not_RB account_VB for_IN the_DT activity_NN of_IN telithromycin_NN against_IN macrolide-resistant_JJ pneumococci_NNS ._SENT Another_DT additional_JJ feature_NN of_IN the_DT ketolides_NNS is_VBZ their_PP$ inability_NN to_TO induce_VB MLSB_NP resistance_NN ._SENT Lack_NN of_IN induction_NN of_IN MLSB_NP resistance_NN with_IN telithromycin_NN is_VBZ due_JJ to_TO the_DT replacement_NN of_IN the_DT l-cladinose_JJ moiety_NN at_IN the_DT C-3_NP position_NN of_IN the_DT lactone_NN ring_NN by_IN a_DT ketone_NN group_NN ._SENT The_DT basal_JJ production_NN of_IN methylase_NN may_MD affect_VB weakly_RB the_DT activities_NNS of_IN telithromycin_NP and_CC ABT773_NP because_IN of_IN their_PP$ affinities_NNS for_IN domain_NN II_NP ._SENT However_RB ,_, constitutive_JJ resistance_NN or_CC high-level_JJ basal_JJ production_NN of_IN methylase_NN remains_VBZ a_DT stumbling_JJ block_NN for_IN the_DT ketolides_NNS ._SENT Compared_VBN to_TO erythromycin_NN ,_, telithromycin_NN is_VBZ a_DT weak_JJ inducer_NN or_CC substrate_NN for_IN the_DT MefA_NP pump_NN ._SENT This_DT fact_NN is_VBZ reflected_VBN by_IN the_DT difference_NN in_IN the_DT increase_NN in_IN MICs_NP due_JJ to_TO this_DT mechanism_NN ,_, 50-fold_NN versus_IN 500-_CD to_TO 2,000-fold_NN ,_, respectively_RB ._SENT In_IN vitro_NN selection_NN of_IN E._NP coli_NNS mutants_NNS highly_RB resistant_JJ to_TO erythromycin_NN has_VBZ been_VBN of_IN considerable_JJ value_NN for_IN characterization_NN of_IN the_DT site_NN of_IN binding_VBG of_IN this_DT antibiotic_NN to_TO the_DT ribosome_NN ._SENT The_DT clinical_JJ importance_NN of_IN this_DT mechanism_NN was_VBD recognized_VBN several_JJ years_NNS ago_RB for_IN microorganisms_NNS such_JJ as_IN Helicobacterpylori_NP and_CC Mycobacteriumavium_NP but_CC only_RB recently_RB for_IN pneumococci_NNS ._SENT Studies_NNS with_IN pneumococcal_JJ mutants_NNS obtained_VBN in_IN the_DT laboratory_NN have_VBP revealed_VBN that_IN several_JJ structures_NNS participating_VBG in_IN the_DT binding_NN of_IN macrolides_NNS ,_, domains_NNS V_CD and_CC II_NP of_IN 23S_JJ rRNA_NNS and_CC proteins_NNS L22_NP and_CC L4_NP ,_, can_MD display_VB mutations_NNS responsible_JJ for_IN macrolide_NN resistance_NN ._SENT Most_JJS mutations_NNS affect_VBP 23S_JJ rRNA_NN and_CC are_VBP similar_JJ to_TO those_DT reported_VBN for_IN other_JJ bacterial_JJ species_NNS ._SENT S._NP pneumoniae_NNS has_VBZ four_CD copies_NNS of_IN the_DT rrl_NN gene_NN for_IN 23S_JJ rRNA_NN ,_, and_CC transformation_NN experiments_NNS with_IN mutated_VBN rrl_NN have_VBP shown_VBN that_DT susceptibility_NN to_TO erythromycin_NN decreases_NNS as_IN the_DT number_NN of_IN the_DT mutated_VBN gene_NN copies_NNS increases_NNS ._SENT Since_IN high-level_JJ erythromycin_NN resistance_NN can_MD be_VB achieved_VBN only_RB when_WRB at_IN least_JJS two_CD copies_NNS are_VBP mutated_VBN ,_, this_DT finding_NN may_MD explain_VB why_WRB resistance_NN conferred_VBD by_IN RNA_NP mutation_NN is_VBZ rare_JJ in_IN pneumococci_NNS compared_VBN to_TO H._NP pylori_NNS or_CC M._NP avium_NN ,_, which_WDT contain_VBP only_RB one_CD or_CC two_CD copies_NNS of_IN the_DT rrl_NN gene_NN ._SENT The_DT resistance_NN phenotype_NN conferred_VBN by_IN alterations_NNS in_IN the_DT 23S_JJ rRNA_NN target_NN varies_VBZ not_RB only_RB according_VBG to_TO the_DT number_NN of_IN mutated_VBN copies_NNS but_CC also_RB according_VBG to_TO the_DT nature_NN of_IN the_DT substituted_VBN base_NN ._SENT Point_NN mutations_NNS at_IN position_NN A2058_NP or_CC A2059_NP are_VBP associated_VBN with_IN phenotypes_NNS similar_JJ to_TO those_DT previously_RB reported_VBN for_IN other_JJ organisms_NNS ._SENT A2058G_NP and_CC A2058U_NP substitutions_NNS confer_VBP the_DT highest_JJS level_NN of_IN MLSB_NP resistance_NN ,_, with_IN MICs_NP of_IN erythromycin_NN and_CC related_JJ macrolides_NNS of_IN between_IN 32_CD and_CC >200_JJ mug/ml_NN ._SENT Telithromycin_NP appears_VBZ to_TO be_VB moderately_RB affected_JJ (_( MICs_NP of_IN 0.06_CD to_TO 1_CD mug/ml_NN )_) ,_, probably_RB because_IN of_IN the_DT alternative_JJ interaction_NN with_IN domain_NN II_NP ._SENT Streptogramins_NNS retain_VBP activity_NN ,_, since_IN synergy_NN between_IN the_DT A_NP and_CC B_NP factors_NNS is_VBZ maintained_VBN ._SENT The_DT A2059G_NP mutation_NN confers_VBZ a_DT high_JJ level_NN of_IN resistance_NN to_TO erythromycin_NN ,_, azithromycin_NN ,_, and_CC 16-membered_JJ macrolides_NNS ,_, a_DT moderate_JJ level_NN of_IN resistance_NN to_TO clarithromycin_NN and_CC clindamycin_NN ,_, but_CC no_DT resistance_NN to_TO streptogramins_NNS ,_, defining_VBG the_DT ML_NP resistance_NN phenotype_NN ._SENT Mutations_NNS at_IN position_NN 2611_CD destabilize_VBP the_DT base_NN pairing_VBG G2057-C2611_NP in_IN the_DT single-strand_NN structure_NN of_IN the_DT central_JJ loop_NN ._SENT However_RB ,_, the_DT C2611U_NP substitution_NN generally_RB has_VBZ a_DT weak_JJ impact_NN on_IN the_DT MICs_NN of_IN macrolides_NNS ._SENT Tait-Kamradt_NP et_FW al._FW found_VBD higher_JJR levels_NNS of_IN resistance_NN to_TO streptogramin_NP B_NP antibiotics_NNS conferred_VBD by_IN C2611A_NP and_CC C2611G_NP substitutions_NNS ._SENT The_DT C2610U_NP change_NN has_VBZ been_VBN reported_VBN only_RB for_IN pneumococci_NNS and_CC yields_VBZ a_DT slight_JJ increase_NN in_IN the_DT MICs_NN of_IN macrolides_NNS and_CC clindamycin_NN ._SENT While_IN telithromycin_NN activity_NN is_VBZ only_RB moderately_RB altered_VBN by_IN mutations_NNS in_IN domain_NN V_NN ,_, mutation_NN of_IN the_DT adenine_NN at_IN position_NN 752_CD in_IN hairpin_NN 35_CD (_( domain_NN II_NP )_) has_VBZ a_DT deleterious_JJ effect_NN on_IN the_DT activity_NN of_IN the_DT drug_NN ._SENT A_DT mutant_NN combining_VBG a_DT deletion_NN of_IN this_DT base_NN and_CC a_DT domain_NN V_NN mutation_NN is_VBZ resistant_JJ not_RB only_RB to_TO 14-_CD and_CC 15-membered_JJ macrolides_NNS but_CC also_RB to_TO telithromycin_NP (_( MIC_NP ,_, 4_CD mg/liter_NN )_) ,_, confirming_VBG the_DT importance_NN of_IN domain_NN II_NP in_IN the_DT mechanism_NN of_IN action_NN of_IN this_DT antibiotic_NN ._SENT Various_JJ mutations_NNS in_IN the_DT rplV_NP (_( L22_NP )_) and_CC rplD_NP (_( L4_NP )_) genes_NNS have_VBP been_VBN shown_VBN to_TO play_VB a_DT role_NN in_IN resistance_NN in_IN laboratory_NN mutants_NNS and_CC in_IN transformants_NNS of_IN a_DT susceptible_JJ S._NP pneumoniae_NNS strain_NN obtained_VBN with_IN mutated_VBN genes_NNS ._SENT The_DT mutations_NNS in_IN the_DT L22_NP protein_NN are_VBP located_VBN in_IN a_DT beta-hairpin_NN extension_NN at_IN the_DT C_NP terminus_NN of_IN the_DT protein_NN ._SENT They_PP confer_VBP resistance_NN to_TO streptogramins_NNS and_CC low-level_JJ resistance_NN to_TO macrolides_NNS ,_, whereas_IN clindamycin_NN does_VBZ not_RB seem_VB to_TO be_VB affected_VBN ._SENT The_DT MICs_NN of_IN telithromycin_NN are_VBP increased_VBN but_CC remain_VB below_IN 0.25_CD mug/ml_NN ._SENT The_DT mutations_NNS in_IN the_DT L4_NP protein_NN occur_VBP in_IN a_DT region_NN of_IN 32_CD amino_NN acids_NNS highly_RB conserved_VBN in_IN various_JJ species_NNS and_CC interfere_VB with_IN the_DT binding_NN of_IN the_DT protein_NN to_TO rRNA_NN ._SENT These_DT mutations_NNS generally_RB confer_VBP an_DT MSB_NP resistance_NN phenotype_NN ._SENT The_DT MICs_NN of_IN macrolides_NNS against_IN the_DT mutant_JJ strains_NNS are_VBP moderately_RB increased_VBN ._SENT Studies_NNS by_IN three-dimensional_JJ cryoelectron_NN microscopy_NN of_IN erythromycin-resistant_JJ ribosomes_NNS of_IN E._NP coli_NNS have_VBP shown_VBN that_IN L4_NP and_CC L22_NP mutants_NNS have_VBP substantial_JJ changes_NNS in_IN the_DT polypeptide_NN tunnel_NN ._SENT The_DT L4_NP mutant_NN which_WDT does_VBZ not_RB bind_NN erythromycin_NN has_VBZ a_DT narrowing_NN of_IN the_DT tunnel_NN entrance_NN which_WDT probably_RB decreases_VBZ the_DT capacity_NN of_IN erythromycin_NN to_TO come_VB into_IN contact_NN with_IN its_PP$ target_NN ._SENT In_IN contrast_NN ,_, the_DT L22_NP mutant_NN has_VBZ an_DT enlargement_NN of_IN the_DT entrance_NN and_CC could_MD bind_VB erythromycin_NN but_CC in_IN an_DT ineffective_JJ way_NN ._SENT Many_JJ of_IN the_DT mutations_NNS selected_VBN in_IN vitro_NP have_VBP been_VBN predictive_JJ of_IN those_DT found_VBN in_IN clinical_JJ isolates_NNS ._SENT The_DT A2059G_NP mutation_NN confers_VBZ an_DT ML_NP resistance_NN phenotype_NN ._SENT A_DT C2611G_NP mutation_NN was_VBD found_VBN in_IN an_DT isolate_NN from_IN Finland_NP that_WDT was_VBD resistant_JJ to_TO macrolides_NNS and_CC highly_RB resistant_JJ to_TO streptogramin_NP B_NP antibiotics_NNS ._SENT Two_CD types_NNS of_IN rplD_NN mutations_NNS in_IN clinical_JJ isolates_NNS have_VBP been_VBN characterized_VBN ._SENT Sixteen_CD isolates_NNS from_IN Eastern_NP Europe_NP which_WDT were_VBD resistant_JJ to_TO penicillin_NN G_NP and_CC a_DT Finnish_JJ isolate_NN contained_VBD substitutions_NNS of_IN three_CD amino_NN acids_NNS (_( 69GTG71_JJ ->_NN 69TPS71_JJ )_) and_CC displayed_VBD an_DT MSB_NP resistance_NN phenotype_NN with_IN a_DT high_JJ level_NN resistance_NN to_TO macrolides_NNS ._SENT A_DT Canadian_JJ isolate_NN had_VBD a_DT six-amino-acid_JJ insertion_NN (_( underlined_VBN )_) ,_, 71GREKGTGR72_NP ,_, and_CC displayed_VBD a_DT similar_JJ phenotype_NN but_CC with_IN a_DT moderate_JJ level_NN of_IN resistance_NN to_TO all_DT macrolides_NNS ,_, including_VBG telithromycin_NN (_( MIC_NP ,_, 3.12_CD mug/ml_NN )_) ._SENT Recently_RB ,_, three_CD strains_NNS isolated_VBN in_IN Japan_NP and_CC for_IN which_WDT the_DT MICs_NN of_IN erythromycin_NN were_VBD 64_CD or_CC 128_CD mug/ml_NN were_VBD reported_VBN to_TO have_VB an_DT L22_NP mutation_NN (_( D._NP J._NP Farrell_NP ,_, I._NP Morrissey_NP ,_, S._NP Bakker_NP ,_, D._NP Felmingham_NP ,_, J._NP Poehlsgaard_NP ,_, and_CC S._NP Douthwaite_NP ,_, Abstr_NP ._SENT 41st_NP Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstr_NN ._SENT 1811_CD ,_, p._NN 100_CD ,_, 2001_CD )_) ._SENT The_DT recent_JJ report_NN of_IN the_DT emergence_NN of_IN an_DT L22_NP mutant_NN during_IN treatment_NN with_IN azithromycin_NN of_IN fatal_JJ pneumococcal_JJ pneumonia_NN emphasizes_VBZ the_DT clinical_JJ importance_NN of_IN mutations_NNS as_IN a_DT resistance_NN mechanism_NN ._SENT In_IN summary_NN ,_, if_IN ,_, as_IN expected_VBN ,_, L4_NP and_CC L22_NP mutants_NNS selected_VBN in_IN vivo_JJ or_CC in_IN vitro_NN have_VBP similar_JJ phenotypes_NNS ,_, the_DT MICs_NNS are_VBP surprisingly_RB higher_JJR for_IN the_DT clinical_JJ isolates_NNS ._SENT The_DT reasons_NNS for_IN this_DT difference_NN are_VBP unknown_JJ but_CC may_MD be_VB related_VBN ,_, at_IN least_JJS for_IN L4_NP mutations_NNS ,_, to_TO differences_NNS in_IN the_DT types_NNS of_IN mutations_NNS ._SENT Alternatively_RB ,_, other_JJ mechanisms_NNS of_IN resistance_NN to_TO macrolide-lincosamide-streptogramin_JJ B_NP antibiotics_NNS may_MD also_RB be_VB present_JJ in_IN wild_JJ strains_NNS ._SENT A_DT clinical_JJ isolate_NN with_IN an_DT A2062C_NP mutation_NN not_RB obtained_VBD so_RB far_RB in_IN vitro_NN had_VBD a_DT particular_JJ phenotype_NN of_IN a_DT high_JJ level_NN of_IN resistance_NN to_TO spiramycin_NN and_CC streptogramin_NN B_NN and_CC a_DT moderate_JJ level_NN of_IN resistance_NN to_TO streptogramins_NP A_NP and_CC B_NP and_CC to_TO the_DT combination_NN ._SENT It_PP remained_VBD susceptible_JJ to_TO 14-_CD and_CC 15-membered_JJ macrolides_NNS ,_, to_TO telithromycin_NN ,_, and_CC to_TO clindamycin_NN ._SENT This_DT new_JJ phenotype_NN confirms_VBZ the_DT notion_NN that_IN the_DT binding_JJ sites_NNS of_IN 14-_CD and_CC 16-membered_JJ macrolides_NNS are_VBP distinct_JJ ._SENT FIG._NN 2_CD ._SENT |_SYM Secondary_JJ structures_NNS of_IN hairpin_NN 35_CD in_IN domain_NN II_NP (_( top_NN )_) and_CC in_IN domain_NN V_CD (_( bottom_NN )_) of_IN 23S_JJ rRNA_NN in_IN E._NP Secondary_JJ structures_NNS of_IN hairpin_NN 35_CD in_IN domain_NN II_NP (_( top_NN )_) and_CC in_IN domain_NN V_CD (_( bottom_NN )_) of_IN 23S_JJ rRNA_NN in_IN E._NP coli_NNS ._SENT Nucleotides_NNS which_WDT are_VBP protected_VBN by_IN erythromycin_NN are_VBP circled_VBN ._SENT Arrows_NNS indicate_VBP mutations_NNS conferring_VBG macrolide_NN resistance_NN on_IN S._NP pneumoniae_NNS ._SENT The_DT corresponding_JJ phenotype_NN is_VBZ indicated_JJ (_( K_NP ,_, ketolides_NNS ;_: L_NP ,_, lincosamides_NNS ;_: M_NP ,_, macrolides_NNS ;_: M16_NP ,_, 16-membered_JJ macrolides_NNS ;_: SB_NP ,_, streptogramin_NP B_NP ;_: S_NP ,_, streptogramin_NP A_NP and_CC streptogramin_NP B_NP )_) ._SENT Small_JJ capital_NN letters_NNS denote_VBP low-level_JJ resistance_NN ._SENT TABLE_NN 2_CD |_SYM MICs_NN of_IN macrolides_NNS and_CC related_JJ antibiotics_NNS for_IN ribosomal_JJ mutants_NNS of_IN S._NP pneumoniae_NNS selected_VBN in_IN vitro_NP TABLE_NP 3_CD |_SYM MICs_NN of_IN macrolides_NNS and_CC related_JJ antibiotics_NNS for_IN ribosomal_JJ mutants_NNS of_IN clinical_JJ isolates_NNS of_IN S._NP pneumoniae_NNS In_IN recent_JJ years_NNS ,_, both_CC the_DT incidence_NN of_IN macrolide_NN resistance_NN in_IN pneumococci_NNS and_CC the_DT variety_NN of_IN resistance_NN mechanism_NN have_VBP increased_VBN sharply_RB ._SENT The_DT emergence_NN of_IN resistance_NN mechanisms_NNS conferred_VBN by_IN mutational_JJ alterations_NNS ,_, in_IN particular_JJ ,_, is_VBZ intriguing_JJ ._SENT This_DT type_NN of_IN resistance_NN may_MD have_VB remained_VBN undetected_JJ in_IN the_DT past_NN because_IN of_IN a_DT lack_NN of_IN adequate_JJ techniques_NNS or_CC ,_, alternatively_RB ,_, resistant_JJ mutants_NNS may_MD have_VB emerged_VBN and_CC spread_VBN recently_RB ._SENT It_PP is_VBZ conceivable_JJ that_IN the_DT use_NN of_IN new_JJ ,_, long-acting_VBG macrolides_NNS with_IN different_JJ pharmacokinetics_NNS may_MD have_VB contributed_VBN to_TO modulation_NN of_IN the_DT selective_JJ pressure_NN exerted_VBN against_IN pneumococci_NNS and_CC to_TO selection_NN of_IN new_JJ resistance_NN genotypes_NNS ._SENT The_DT variety_NN of_IN resulting_VBG phenotypes_NNS makes_VBZ it_PP particularly_RB challenging_JJ to_TO detect_VB the_DT nature_NN of_IN resistance_NN in_IN clinical_JJ isolates_NNS and_CC may_MD lead_VB to_TO difficulties_NNS in_IN or_CC make_VB impossible_JJ the_DT detection_NN of_IN resistance_NN ,_, depending_VBG on_IN the_DT individual_JJ drug(s)_NN being_VBG tested_VBN ._SENT 